Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition
A total of 22 abstracts have been accepted, predominantly data in several types of blood cancers, including leukemia, lymphoma and myeloma. Read more
Exploration of Genomic Ancestry in B-Cell Malignancies Identifies Multiple Important Genomic Differences
Investigators from Foundation Medicine, Inc. and Rutgers Cancer Institute of New Jersey examined genomic ancestry in BCL subtypes applying genomic ancestry prediction methodology to comprehensive genomic profiling data and found multiple genomic differences. Read more
Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma
In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.Read more
Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2
Researchers from Rutgers Cancer Institute evaluated the frequency of SARS-CoV-2 on various environmental surfaces in outpatient and inpatient hematology/oncology settings within Rutgers Cancer Institute and Robert Wood Johnson University Hospital. Read more
Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients
In a retrospective review, members of the Hematologic Malignancies Program at Rutgers Cancer Institute examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established CDI, as a way to prevent CDI in these patients. Read more
Presentations by Rutgers Cancer Institute of New Jersey Faculty Members at the 2020 American Society of Hematology Annual Meeting & Exposition
Monday, December 7, 2020
7:00 am – 3:30 pm
- Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population (Session # 721)
Authors: Anne A Tyno, RN, MSN, APN-C, Vimal Patel, MD, Dale G. Schaar, MD, Roger Strair, MD, PhD
Senior Author: Dennis Cooper, MD
Program: Poster - Radiation-Based Approaches as an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis (Session # 624)
Author: Andrew M. Evens, DO, MMSc
Program: Poster - EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort (Session # 627)
Authors: Kevin David, MD, Andrew M. Evens, DO, MMSc
Program: Poster
7:45 am
- Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor (Session # 605)
Author: Daniel Herranz, PharmD. PhD
Program: Oral
9:30 am
- Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study (Session # 626)
Author: Rajat Bannerji, MD, PhD
Program: Oral
10:00 am
- Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001 (Session # 612)
Author: Peter D. Cole, MD
Program: Oral
1:30 pm
- The Burkitt Lymphoma International Prognostic Index (BL-IPI) (Session # 627)
Senior Author: Andrew M. Evens, DO, MMSc
Program: Oral
1:45 pm
- Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis (Session # 627)
Author: Andrew M. Evens, DO, MMSc
Program: Oral